ePT News April 2004

A new bioanalytical lab being opened by Ardena at the site is expected to be operational by the third quarter of 2025.

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

Process consistency and robustness, analytical excellence, and regulatory compliance are essential in the scale-up of biosimilars.

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

Developers save money and time while accessing expertise.

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.